Regulation of 11β-hydroxysteroid dehydrogenase type 2 by diuretics and the renin-angiotensin-aldosterone axis

Clinical Science

Volumn 96, Issue 6, 1999, Pages 669-675

  Ricketts, Marie L ^a,b   Stewart, Paul M ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

11 hydroxysteroid dehydrogenase type 2; Diuretics; Regulation; Renin angiotensin aldosterone axis

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; ANGIOTENSIN; ATRIAL NATRIURETIC FACTOR; BRADYKININ; CAPTOPRIL; CORTISONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FOSINOPRIL; FUROSEMIDE; HYDROCHLOROTHIAZIDE; HYDROCORTISONE; KIDNEY ENZYME; LISINOPRIL; MINERALOCORTICOID RECEPTOR; PERINDOPRIL; QUINAPRIL; TRANDOLAPRIL; ANGIOTENSIN II; CARBENOXOLONE; HYDROXYSTEROID DEHYDROGENASE; VASOCONSTRICTOR AGENT;

ARTICLE; BLOOD PRESSURE REGULATION; CELL LINE; COLON; CONTROLLED STUDY; DRUG MECHANISM; ENZYME DEFICIENCY; ENZYME KINETICS; ENZYME REGULATION; HOMEOSTASIS; HUMAN; HUMAN CELL; HYPERTENSION; KIDNEY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SODIUM RETENTION; SODIUM URINE LEVEL; TARGET ORGAN; CELL CULTURE; DOSE RESPONSE; DRUG EFFECT; ENZYMOLOGY; METABOLISM; PHYSIOLOGY;

11-BETA-HYDROXYSTEROID DEHYDROGENASES; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARBENOXOLONE; COLON; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROCHLOROTHIAZIDE; HYDROXYSTEROID DEHYDROGENASES; RENIN-ANGIOTENSIN SYSTEM; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED; VASOCONSTRICTOR AGENTS;

EID: 0033029975     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS19980353     Document Type: Article

References (34)

1. Monder, C. and White, P. C. (1993) 11β-Hydroxysteroid dehydrogenase. Vitam. Horm. 47, 187-271
2. Tannin, G. M., Agarwal, A. K., Monder, C., New, M. I. and White, P. C. (1991) The human gene for 11β-hydroxysteroid dehydrogenase. Structure, tissue distribution, and chromosomal localization. J. Biol. Chem. 266, 16653-16658
3. Stewart, P. M., Murry, B. A. and Mason, J. I. (1994) Human kidney 11β-hydroxysteroid dehydrogenase is a high affinity NAD-dependent enzyme and differs from the cloned 'type 1' isoform. J. Clin. Endocrinol. Metab. 79, 480-484
4. Whorwood, C. B., Mason, J. I., Ricketts, M. L., Howie, A. J. and Stewart, P. M. (1995) Detection of human 11β-hydroxysteroid dehydrogenase isoforms using reverse-transcriptase polymerase chain reaction and localization of the type 2 isoform to renal collecting ducts. Mol. Cell Endocrinol. 110, R7-R12
5. Jamieson, P. M., Chapman, K. E., Edwards, C. R. W. and Seckl, J. R. (1995) 11β-Hydroxysteroid dehydrogenase is in exclusive 11β-reductase in primary cultures of rat hepatocytes: effect of physicochemical and hormonal manipulations. Endocrinology (Baltimore) 136, 4754-4761
6. Ricketts, M. L., Shoesmith, K. J., Hewison, M., Strain, A., Eggo, M. C. and Stewart, P. M. (1998) Regulation of 11β-hydroxysteroid dehydrogenase type 1 in primary cultures of rat and human hepatocytes. J. Endocrinol. 156, 159-168
7. Albiston, A. L., Obeyesekene, V. R., Smith, R. E. and Krozowski, Z. S. (1994) Cloning and tissue distribution of the human 11β-hydroxysteroid dehydrogenase type 2 enzyme. Mol. Cell Endocrinol. 105, R11-R17
8. Whorwood, C. B., Ricketts, M. L. and Stewart, PM. (1994) Epithelial cell localization of type 2 11β-hydroxysteroid dehydrogenase in rat and human colon. Endocrinology (Baltimore) 135, 2533-2541
9. Wilson, R. C., Krozowski, Z. S., Li, K. et al. (1995) A mutation in the HSDIIB2 gene in a family with apparent mineralocorticoid excess. J. Clin. Endocrinol. 80, 2263-2266
10. Mune, T., Rogerson, F. M., Nikkila, H., Agarwal, A. K. and White, P. C. (1995) Human hypertension caused by mutations in the kidney isozyme of 11β-hydroxysteroid dehydrogenase. Nat. Genet. 10, 394-399
11. Stewart, P. M., Krozowski, Z. S., Gupta, A. et al. (1996) Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11β-hydroxysteroid dehydrogenase type 2 gene. Lancet 347, 88-91
12. Stewart, P. M., Walker, B. R., Holder, G., O'Halloran, D. and Shackleton, C. H. L. (1995) 11β-Hydroxysteroid dehydrogenase activity in Cushing's syndrome: explaining the mineralocorticoid excess state of the ectopic adrenocorticotropin syndrome. J. Clin. Endocrinol. Metab. 80, 3617-3620
13. Brown, R. W., Chapman, K. E., Edwards, C. R. W. and Seckl, J. R. (1993) Human placental 11β-hydroxysteroid dehydrogenase: evidence for and partial purification of a distinct NAD-dependent isoform. Endocrinology (Baltimore) 132, 2614-2621
14. Benediktsson, R., Lindsay, R., Noble, J., Seckl, J. R. and Edwards, C. R. W. (1993) Glucocorticoid exposure: a new model for adult hypertension. Lancet 341, 339-341
15. Bujalska, I. J., Shimojo, M., Howie, A. J. and Stewart, P. M. (1997) Human 11β-hydroxysteroid dehydrogenase: studies on the stably transfected isoforms and localization of the type 2 isozyme within renal tissue. Steroids 62, 77-82
16. Chomczynski, P. and Sacchi, N. (1987) Single step method of RNA isolation by acid guanidium thiocyanite phenol chloroform extraction. Anal. Biochem. 162, 156-159
17. Navis, G., de Jong, P. E., Donker, A. J. M., van der Hem, G. K. and de Zeeuw, D. (1987) Diuretic effects of angiotensin-converting enzyme inhibition: comparison of low and liberal sodium diet in hypertensive patients. J. Cardiovasc. Pharmacol. 9, 743-748
18. Leonetti, G. and Cuspidi, C. (1995) Choosing the right ACE inhibitor: a guide to selection. Drugs 49, 516-535
19. White, P. C., Mune, T. and Agarwal, A. K. (1997) 11β-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr. Rev. 18, 135-156
20. Li, A., Tedde, R., Krozowski, Z. S. et al. (1998) Molecular basis for hypertension in the 'type II variant' of apparent mineralocorticoid excess. Am. J. Hum. Genet. 63, 370-379
21. Walker, B. R., Campbell, J. C., Fraser, R., Stewart, P. M. and Edwards, C. R. W. (1992) Mineralocorticoid excess and inhibition of 11β-hydroxysteroid dehydrogenase in patients with ectopic ACTH syndrome. Clin. Endocrinol. 37, 483-492
22. Soro, A., Ingram, M. C., Tonolo, G., Glorioso, N. and Fraser, R. (1995) Evidence of coexisting changes in 11β-hydroxysteroid dehydrogenase and 5β-reductase activity in patients with untreated essential hypertension. Hypertension 25, 67-70
23. Blaine, E. H., Seymour, A. A., Marsh, E. A. and Napier, M. A. (1986) Effects of atrial natriuretic factor on renal function and cyclic GMP production. Fed. Proc. 45, 2122-2127
24. Camargo, M. J. F., Kleinert, H. D., Atlas, S. A., Laragh, J. H. and Maack, T. (1984) Calcium-dependent hemodynamic and natriuretic effects of atrial extract in isolated rat kidney. Am. J. Physiol. 246, F447-F456
25. Carretero, O. A. and Scilili, A. G. (1989) Kinins, paracrine hormones, in the regulation of blood flow, renal function, and blood pressure. In Endocrine Mechanisms in Hypertension (Laragh, J. H., Brenner, B. M. and Kaplan, N. M., eds.), Perspectives in Hypertension, vol. 2, pp. 219-239, Raven Press, New York
26. Zhang, Y. D., Lorenzo, B. and Reidenberg, M. M. (1994) Inhibition of 11β-hydroxysteroid dehydrogenase obtained from guinea pig kidney by furosemide, naringenin and some other compounds. J. Steroid Biochem. Mol. Biol. 49, 81-85
27. Escher, G., Meyer, K. V., Vishwanath, B. S., Frey, B. M. and Frey, F. J. (1995) Furosemide inhibits 11β-hydroxysteroid dehydrogenase in vitro and in vivo. Endocrinology (Baltimore) 136, 1759-1765
28. Fuster, D., Escher, G., Vogt, B. et al. (1998) Furosemide inhibits 11β-hydroxysteroid dehydrogenase type 2. Endocrinology (Baltimore) 139, 3849-3854
29. Niepel, T., Maser, E. and Hermans, J. J. R. (1997) The effect of amiloride and sodium chloride on rat renal and hepatic 11β-hydroxysteroid dehydrogenase activities. Pharmacol. Toxicol. 80, 127-131
30. Low, S. C., Assaad, S. N., Rajan, V., Chapman, K. E., Edwards, C. R. W. and Seckl, J. R. (1993) Regulation of 11β-hydroxysteroid dehydrogenase by sex steroids in vivo: further evidence for the existence of a second dehydrogenase in rat kidney. J. Endocrinol. 139, 27-35
31. Riddle, M. C. and McDaniel, P. A. (1994) Renal 11β-hydroxysteroid dehydrogenase activity is enhanced by ramipril and captopril. J. Clin. Endocrinol. Metab. 78, 830-834
32. Dullaart, R. P. F., Ubels, F. L., Hoogenberg, K. et al. (1995) Alterations in cortisol metabolism in insulin-dependent diabetes mellitus: relationship with metabolic control and estimated blood volume and effect of angiotensin-converting enzyme inhibition. J. Clin. Endocrinol. Metab. 80, 3002-3008
33. Seymour, A. A., Asaad, M. M., Abboa-Offei, B. E. et al. (1996) Renal and depressor activities of inhibitors of neutral endopeptidase and angiotensin converting enzyme in monkeys infused with angiotensin II. J. Cardiol. Pharmacol. 28, 651-658
34. Seymour, A. A., Asaad, M. M., Abboa-Offei, B. E., Smith, P. L., Rogers, W. L. and Dorso, C. R. (1996) Determinants of in vivo activity of neutral endopeptidase 3.4.24.11 and angiotensin converting enzyme inhibitors. J. Pharmacol. Exp. Ther. 276, 708-713